Atea Pharmaceuticals Inc. reported its financial results for the third quarter ended September 30, 2025. The company reported cash, cash equivalents, and marketable securities totaling $329.3 million as of the end of the quarter, compared to $454.7 million at the end of the previous period. Working capital was $316.0 million, down from $443.8 million. Total assets were $343.0 million, with total liabilities of $27.2 million and total stockholder's equity of $315.8 million. Atea provided a business update, noting that patient enrollment is on track in its global Phase 3 program for the treatment of hepatitis C virus (HCV), with topline results from the North America trial expected in mid-2026. The company also announced new data showing that bemnifosbuvir has a unique dual mechanism against HCV, and presented results supporting the combination of bemnifosbuvir/ruzasvir as a potential best-in-class therapy for HCV. Additionally, Atea announced the initiation of a new hepatitis E virus (HEV) development program.